News

Dr. Holly Andrews wasn't necessarily drawn to agricultural research, but her passion for ecosystem science, from parks to wetlands to the desert, has led her to tease apart the physics of soil to find more sustainable solutions for current agricultural practices.

A study led by BIO5 member Lalitha Madhavan has developed an improved method to study Parkinson’s disease in the lab. Along the way, the lab has also uncovered clues that may help scientists figure out how to detect Parkinson’s earlier — and point the way toward better treatments.

BIO5 member Marvin Slepian and a team of University of Arizona Health Sciences researchers found that when it comes to diagnosis and treatment, about half of the participants said they preferred a human doctor over AI.

BIO5 member Janko Ž. Nikolich and his research team at the University of Arizona College of Medicine - Tucson have been awarded grant funding to investigate strategies that kickstart the aging immune system.

Dr. Rebekah Mokry talks about how the guidance of supportive mentors helped her find impactful research that focuses on the inner workings of a dangerous virus.

A $1.5 million grant from the Department of Defense will help BIO5 member William “Scott” Killgore and his team create a portable virtual reality device to quickly assess traumatic brain injuries when and where they occur.

It is with profound sorrow that we share the heartbreaking news of the passing of our esteemed colleague, Dr. John Paul SanGiovanni. He passed away unexpectedly on Monday, September 25, and his loss is felt by all of us at the University of Arizona and the BIO5 Institute.

BIO5 member John Galgiani founded the Valley Fever Collaborative that unites the University of Arizona, Arizona State University and Northern Arizona University researchers in their efforts to understand the disease better, develop rapid diagnostic tests, find a cure and develop a preventative vaccine for Valley fever.

Epidemiologist and BIO5 member Kristen Pogreba-Brown will part of a study investigating the incidence of irritable bowel syndrome (IBS) as a Long COVID symptom.